ADPT President and COO Julie Rubinstein Sells $309K of Stock

On October 26, 2026, Julie Rubinstein, the President and COO of Adaptive Biotechnologies Corporation (ADPT), sold 11,881 shares at a price of $26.04 each, totaling approximately $309,410. This transaction was part of a pre-arranged trading plan, as noted in the Form 4 filing with the SEC.

ADPT Adaptive Biotechnologies Corporation

$25.51 ▲ +60.34% year to date

1M 3M YTD

Daily close · Oct 23, 2026

Inside Julie Rubinstein's Trade

Rubinstein's sale reduced her ownership by about 3.05%, leaving her with 377,802 shares. The sale comes at a time when the stock is trading near its recent levels, closing at $26.27 on the same day.

Other Institutional Activity in Adaptive Biotechnologies

Viking Global Investors, L.P. holds 29,993,708 shares of Adaptive Biotechnologies, valued at about $787.9 million. Shaw D.E. & Co., Inc. increased its stake by 2,660,252 shares, bringing its total to 4,625,859 shares worth approximately $121.5 million. Meanwhile, Westfield Capital Management Co LP cut its position by 1,168,845 shares, now holding 4,267,645 shares valued at about $112.1 million.

Adaptive Biotechnologies Corporation Stock Up 7.6%

The stock is recently trading at $26.27, which is about equal to its closing price on October 26, 2026. It is above its 50-day moving average by roughly 0.5% and significantly above its 200-day moving average by about 35.8%. However, it remains below its 52-week high of $30.74 by about 14.5%.

Recent Earnings

For the trailing twelve months, Adaptive Biotechnologies reported revenue of $308.1 million, with a year-over-year growth of 21.5%. The company has not yet turned a profit, with a net margin of -20.7% and a return on equity of -38.8%. The next earnings report is scheduled for November 4, 2026.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

This sale marks Julie Rubinstein's fourth transaction within a week, selling a total of 47,524 shares across multiple days. Her earlier sales were executed on October 16, 19, 20, and 21, 2026, at prices ranging from $24.05 to $25.41 each.

Analysts Set New Price Targets

On September 22, 2026, BTIG maintained a Buy rating with a price target of $34.00, up from $25.00. Goldman Sachs initiated coverage on September 29, 2026, also with a Buy rating and a target of $35.00. Guggenheim and TD Cowen both maintained Buy ratings, with target prices of $32.00, while Morgan Stanley has an Equal-Weight rating with a target of $27.00.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation develops an immune medicine platform for diagnosing and treating various diseases. The company uses a unique immunosequencing platform that combines proprietary chemistry and machine learning to generate clinical data about the adaptive immune system. This innovative approach is key to understanding and treating complex diseases.

Bottom Line

Investors should keep an eye on Adaptive Biotechnologies, especially as the next earnings date approaches on November 4, 2026. With Rubinstein's recent trades and analysts maintaining positive ratings, there may be further developments to watch in the coming weeks.